Tatva Chintan Pharma Chem Share Price
Sector: Chemical Manufacturing
950.75 +7.75 (0.82%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
930
Today’s High
964.40
52 Week Low
610
52 Week High
1195.05
949.40 +6.15 (0.65%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
944
Today’s High
967.50
52 Week Low
621
52 Week High
1199.95
Key Metrics
- Market Cap (In Cr) 2227.63
- Beta 0.72
- Div. Yield (%) 0.11
- P/B 2.99
- TTM P/E 277.52
- Peg Ratio -6.23
- Sector P/E 17.69
- D/E 0
- Open Price 930
- Prev Close 943
Tatva Chintan Pharma Chem Analysis
Price Analysis
-
1 Week2.82%
-
3 Months39.3%
-
6 Month9.78%
-
YTD6.04%
-
1 Year-14.03%
Risk Meter
- 50% Low risk
- 50% Moderate risk
- 50% Balanced Risk
- 50% High risk
- 50% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 2
- 2
- 2
- 2
- Buy
- 1
- 1
- 1
- 1
- Hold
- 1
- 1
- 1
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 1
- Strong Sell
- 1
- 1
- 1
- 1
- Total
- 5
- 5
- 5
- 5
Tatva Chintan Pharma Chem News
Stocks to buy: Anand Rathi recommends these stocks as Emerging Picks for October
1 min read . 10 Oct 2024Tatva Chintan Pharma Chem Q1 Results Live : profit falls by 45.19% YOY
1 min read . 26 Jul 2024SRF, Navin Fluorine and more: 4 stocks that will likely gain from agrochemical cycle rebound
3 min read . 24 Jun 2024Stocks to buy: Navin Fluorine, SRF among top 5 chemical stock picks
3 min read . 20 Jun 2024Tatva Chintan Pharma Chem Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 382.71
- Selling/ General/ Admin Expenses Total
- 52.92
- Depreciation/ Amortization
- 27.66
- Other Operating Expenses Total
- 96.64
- Total Operating Expense
- 376.16
- Operating Income
- 6.55
- Net Income Before Taxes
- 7.58
- Net Income
- 5.71
- Diluted Normalized EPS
- 2.44
- Period
- 2025
- Total Assets
- 836.25
- Total Liabilities
- 97.43
- Total Equity
- 738.82
- Tangible Book Valueper Share Common Eq
- 314.51
- Period
- 2025
- Cashfrom Operating Activities
- 24.67
- Cashfrom Investing Activities
- -65.25
- Cashfrom Financing Activities
- 16.57
- Net Changein Cash
- -23.93
- Period
- 2024
- Total Revenue
- 393.5
- Selling/ General/ Admin Expenses Total
- 105.88
- Depreciation/ Amortization
- 25.61
- Other Operating Expenses Total
- 0.06
- Total Operating Expense
- 349.79
- Operating Income
- 43.71
- Net Income Before Taxes
- 43.57
- Net Income
- 30.35
- Diluted Normalized EPS
- 13.31
- Period
- 2024
- Total Assets
- 818.72
- Total Liabilities
- 81.64
- Total Equity
- 737.08
- Tangible Book Valueper Share Common Eq
- 314.95
- Period
- 2024
- Cashfrom Operating Activities
- 98.04
- Cashfrom Investing Activities
- -120.54
- Cashfrom Financing Activities
- 30.52
- Net Changein Cash
- 7.94
- Period
- 2023
- Total Revenue
- 423.61
- Selling/ General/ Admin Expenses Total
- 97.39
- Depreciation/ Amortization
- 9.56
- Other Operating Expenses Total
- 0.13
- Total Operating Expense
- 365.28
- Operating Income
- 58.34
- Net Income Before Taxes
- 44.78
- Net Income
- 45.49
- Diluted Normalized EPS
- 21.57
- Period
- 2023
- Total Assets
- 758.86
- Total Liabilities
- 244.07
- Total Equity
- 514.79
- Tangible Book Valueper Share Common Eq
- 232.04
- Period
- 2023
- Cashfrom Operating Activities
- 27.78
- Cashfrom Investing Activities
- -101.14
- Cashfrom Financing Activities
- 37.8
- Net Changein Cash
- -35.65
- Period
- 2022
- Total Revenue
- 433.65
- Selling/ General/ Admin Expenses Total
- 94.83
- Depreciation/ Amortization
- 8.18
- Other Operating Expenses Total
- 0.16
- Total Operating Expense
- 333.46
- Operating Income
- 100.19
- Net Income Before Taxes
- 104.12
- Net Income
- 95.87
- Diluted Normalized EPS
- 44.62
- Period
- 2022
- Total Assets
- 658.3
- Total Liabilities
- 185.21
- Total Equity
- 473.09
- Tangible Book Valueper Share Common Eq
- 213.3
- Period
- 2022
- Cashfrom Operating Activities
- 20.38
- Cashfrom Investing Activities
- -196.81
- Cashfrom Financing Activities
- 234.96
- Net Changein Cash
- 58.54
- Period
- 2021
- Total Revenue
- 300.36
- Selling/ General/ Admin Expenses Total
- 65.57
- Depreciation/ Amortization
- 6.73
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 240.59
- Operating Income
- 59.77
- Net Income Before Taxes
- 60.7
- Net Income
- 52.26
- Diluted Normalized EPS
- 23.59
- Period
- 2021
- Total Assets
- 314.8
- Total Liabilities
- 148.84
- Total Equity
- 165.96
- Tangible Book Valueper Share Common Eq
- 74.83
- Period
- 2021
- Cashfrom Operating Activities
- 19.69
- Cashfrom Investing Activities
- -20.66
- Cashfrom Financing Activities
- -4.71
- Net Changein Cash
- -5.68
- Period
- 2020
- Total Revenue
- 263.24
- Selling/ General/ Admin Expenses Total
- 63.31
- Depreciation/ Amortization
- 4.79
- Total Operating Expense
- 210.85
- Operating Income
- 52.39
- Net Income Before Taxes
- 47.6
- Net Income
- 37.79
- Diluted Normalized EPS
- 17.06
- Period
- 2020
- Total Assets
- 248.94
- Total Liabilities
- 131.24
- Total Equity
- 117.69
- Tangible Book Valueper Share Common Eq
- 53.04
- Period
- 2020
- Cashfrom Operating Activities
- 25.31
- Cashfrom Investing Activities
- -40.18
- Cashfrom Financing Activities
- 9.95
- Net Changein Cash
- -4.92
- Period
- 2025-03-31
- Total Revenue
- 107.86
- Selling/ General/ Admin Expenses Total
- 14.05
- Depreciation/ Amortization
- 7.26
- Other Operating Expenses Total
- 27.18
- Total Operating Expense
- 106.17
- Operating Income
- 1.69
- Net Income Before Taxes
- 2.03
- Net Income
- 1.03
- Diluted Normalized EPS
- 0.44
- Period
- 2025-03-31
- Total Assets
- 836.25
- Total Liabilities
- 97.43
- Total Equity
- 738.82
- Tangible Book Valueper Share Common Eq
- 314.51
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 24.67
- Cashfrom Investing Activities
- -65.25
- Cashfrom Financing Activities
- 16.57
- Net Changein Cash
- -23.93
- Period
- 2024-12-31
- Total Revenue
- 85.9
- Selling/ General/ Admin Expenses Total
- 13.23
- Depreciation/ Amortization
- 6.92
- Other Operating Expenses Total
- 24.07
- Total Operating Expense
- 85.76
- Operating Income
- 0.14
- Net Income Before Taxes
- -0.24
- Net Income
- 0.14
- Diluted Normalized EPS
- 0.06
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 83.49
- Selling/ General/ Admin Expenses Total
- 12.94
- Depreciation/ Amortization
- 6.81
- Other Operating Expenses Total
- 22.24
- Total Operating Expense
- 84.72
- Operating Income
- -1.23
- Net Income Before Taxes
- -1.02
- Net Income
- -0.66
- Diluted Normalized EPS
- -0.29
- Period
- 2024-09-30
- Total Assets
- 807.02
- Total Liabilities
- 69.42
- Total Equity
- 737.6
- Tangible Book Valueper Share Common Eq
- 313.82
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 12.3
- Cashfrom Investing Activities
- -31.43
- Cashfrom Financing Activities
- -3.8
- Net Changein Cash
- -23.09
- Period
- 2024-06-30
- Total Revenue
- 105.46
- Selling/ General/ Admin Expenses Total
- 12.7
- Depreciation/ Amortization
- 6.67
- Other Operating Expenses Total
- 23.16
- Total Operating Expense
- 99.51
- Operating Income
- 5.95
- Net Income Before Taxes
- 6.81
- Net Income
- 5.21
- Diluted Normalized EPS
- 2.23
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 98.27
- Selling/ General/ Admin Expenses Total
- 14.37
- Depreciation/ Amortization
- 6.23
- Other Operating Expenses Total
- 26.81
- Total Operating Expense
- 88.89
- Operating Income
- 9.38
- Net Income Before Taxes
- 13.69
- Net Income
- 9.61
- Diluted Normalized EPS
- 4.11
- Period
- 2024-03-31
- Total Assets
- 818.72
- Total Liabilities
- 81.64
- Total Equity
- 737.08
- Tangible Book Valueper Share Common Eq
- 314.95
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 98.04
- Cashfrom Investing Activities
- -120.54
- Cashfrom Financing Activities
- 30.52
- Net Changein Cash
- 7.94
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Tatva Chintan Pharma Chem Technical
Moving Average
SMA
- 5 Day926.69
- 10 Day928.19
- 20 Day935.48
- 50 Day849.89
- 100 Day777.76
- 300 Day843.54
Tatva Chintan Pharma Chem Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Meghmani Organics
- 99
- 1.47
- 1.51
- 116
- 57
- 2521.37
- Dcw
- 83.38
- 0.27
- 0.32
- 113
- 50
- 2459.16
- Tatva Chintan Pharma Chem
- 950.75
- 7.75
- 0.82
- 1195.05
- 610
- 2227.63
- Panama Petrochem
- 354.35
- -3.4
- -0.95
- 452.45
- 301.3
- 2138.79
- Sigachi Industries
- 48.04
- -7.14
- -12.94
- 69.75
- 34.51
- 1837.01
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Meghmani Organics
- -
- 1.64
- 8.5
- 5.92
- Dcw
- 80.7
- 2.38
- 7.93
- 3.35
- Tatva Chintan Pharma Chem
- 386.58
- 2.99
- 9.9
- 11.88
- Panama Petrochem
- 11.6
- 1.73
- 23.2
- 8.93
- Sigachi Industries
- 26.76
- 3.51
- 17.79
- 14.8
Tatva Chintan Pharma Chem Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 02-May-25
- Audited Results & Final Dividend
- 28-Jan-25
- Quarterly Results
- 25-Oct-24
- Quarterly Results
- 24-Jul-24
- Quarterly Results
- 03-May-24
- Audited Results & Final Dividend
- 20-Jan-24
- Quarterly Results
- 02-Nov-23
- Quarterly Results
- 04-Aug-23
- Quarterly Results
- 11-Jul-23
- Preferential issue of shares
- 05-May-23
- Audited Results & Final Dividend
- Meeting Date
- Announced on
- Purpose
- 20-Sept-24
- 27-Aug-24
- AGM
- 22-Sept-23
- 28-Aug-23
- AGM
- 15-Aug-23
- 14-Jul-23
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 02-May-25
- -
- -
- 1
- 03-May-24
- -
- 06-Sept-24
- 2
- 05-May-23
- -
- 08-Sept-23
- 2
- 25-Apr-22
- 09-Sept-22
- 08-Sept-22
- 2


